中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

545 records (took 0.043 seconds)

    GENES AND POLYPEPTIDES RELATING TO HEPATOCELLULAR OR COLORECTAL CARCINOMA
    21.
    发明申请
    GENES AND POLYPEPTIDES RELATING TO HEPATOCELLULAR OR COLORECTAL CARCINOMA 审中-公开
    与肝细胞癌或染色体癌相关的基因和多肽

    公开(公告)号：WO03104276A9

    公开(公告)日：2004-05-27

    申请号：PCT/JP0307070

    申请日：2003-06-04

    Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI

    Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI

    IPC: C07K14/47 ,  C12N15/12

    CPC classification number: C07K16/303 ,  A61K38/00 ,  C07K14/4748 ,  C07K16/3046 ,  G01N33/57419 ,  G01N33/57438 ,  G01N33/6893 ,  G01N2500/00

    Abstract: The present application provides novel human genes WDRPUH and KRZFPUH, and PPIL1 whose expression is markedly elevated in a great majority of HCCs and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon-cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.

    Abstract translation: 本申请提供了新的人类基因WDRPUH和KRZFPUH，和PPIL1，其表达在大多数HCC和结肠直肠癌中分别与相应的非癌组织相比显着升高，以及新型人基因APCDD1，其表达升高 原发性结肠癌并且响应于野生型APC1转导入结肠癌细胞而下调。 由该基因编码的基因和多肽可用于例如细胞增殖性疾病的诊断，以及用于开发针对该疾病的药物的靶分子。

    PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR LUNG CANCER
    24.
    发明申请
    PROGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR LUNG CANCER 审中-公开
    预测肺癌的预后指标和治疗目标

    公开(公告)号：WO2008023840A2

    公开(公告)日：2008-02-28

    申请号：PCT/JP2007066825

    申请日：2007-08-23

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/158

    Abstract: The present invention provides a diagnostic marker to detecting lung cancer. In particular, the present invention provides lung cancer marker genes i.e. KIF4A, MAPJD, NPTX, or FGFR1OP. The present invention further provides methods and kit for identifying compounds for treating lung cancer as well as methods for predicting a prognosis or diagnosis of lung cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between KIF4A/ZNF549, KIF4A/ZNF553, MAPJD/MYC, or FGFR1OP/WRNIP1 which find utility in the treatment and prevention of lung. Alternatively, the present invention provides MAPJD associated with HAT complex as therapeutic target.

    Abstract translation: 本发明提供了检测肺癌的诊断标记。 具体而言，本发明提供肺癌标志物基因，即KIF4A，MAPJD，NPTX或FGFR1OP。 本发明进一步提供了鉴定用于治疗肺癌的化合物的方法和试剂盒以及预测肺癌预后或诊断的方法。 具体而言，本发明提供了用于鉴定可用于治疗和预防肺的KIF4A / ZNF549，KIF4A / ZNF553，MAPJD / MYC或FGFR1OP / WRNIP1之间相互作用抑制剂的方法和试剂盒。 或者，本发明提供与作为治疗靶标的HAT复合物相关的MAPJD。

    METHOD FOR DIAGNOSING AND TREATING RENAL CELL CARCINOMA
    25.
    发明申请
    METHOD FOR DIAGNOSING AND TREATING RENAL CELL CARCINOMA 审中-公开
    诊断和治疗肾细胞癌的方法

    公开(公告)号：WO2007013575A3

    公开(公告)日：2007-10-25

    申请号：PCT/JP2006314946

    申请日：2006-07-21

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

    Abstract: Objective methods for detecting and diagnosing renal cell carcinoma (RCC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of RCC-associated gene that discriminates between RCC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of renal cell carcinoma, methods of treating renal cell carcinoma and method of vaccinating a subject against renal cell carcinoma.

    Abstract translation: 本文描述了用于检测和诊断肾细胞癌（RCC）的客观方法。 在一个实施方案中，诊断方法包括确定区分RCC细胞和正常细胞的RCC相关基因的表达水平。 本发明进一步提供筛选用于治疗肾细胞癌的治疗剂的方法，治疗肾细胞癌的方法以及针对肾细胞癌接种受试者的方法。

    METHOD OF DIAGNOSING SMALL CELL LUNG CANCER
    26.
    发明申请
    METHOD OF DIAGNOSING SMALL CELL LUNG CANCER 审中-公开
    诊断小细胞肺癌的方法

    公开(公告)号：WO2007013665A3

    公开(公告)日：2007-07-05

    申请号：PCT/JP2006315254

    申请日：2006-07-26

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68 ,  C12N15/113

    CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136

    Abstract: Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.

    Abstract translation: 本文描述了用于检测和诊断小细胞肺癌（SCLC）的客观方法。 在一个实施方案中，诊断方法包括确定区分SCLC细胞和正常细胞的SCLC相关基因的表达水平。 在另一个实施方案中，诊断方法涉及确定区分肺癌，非小细胞肺癌（NSCLC）和SCLC两种主要组织学类型的SCLC相关基因的表达水平。 最后，本发明提供筛选用于治疗小细胞肺癌的治疗剂的方法，治疗小细胞肺癌的方法和用于针对小细胞肺癌接种受试者的方法。 此外，本发明提供化疗耐受性肺癌或SCLC相关基因作为这些癌症的治疗剂的诊断标记和/或分子靶标。 这些基因在化学抗性肺癌或SCLC中上调。 因此，可以使用基因的表达水平作为诊断标记来预测化学抗性肺癌或SCLC。 结果，可以避免由无效化疗引起的任何副作用，并且可以选择更合适和有效的治疗策略。

    METHOD OF DIAGNOSING ESOPHAGEAL CANCER
    27.
    发明申请
    METHOD OF DIAGNOSING ESOPHAGEAL CANCER 审中-公开
    诊断食管癌的方法

    公开(公告)号：WO2007013671A2

    公开(公告)日：2007-02-01

    申请号：PCT/JP2006315342

    申请日：2006-07-26

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  DAIGO YATARO ,  NAKATSURU SHUICHI

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y10T436/25

    Abstract: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, S. cerevisiae, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.

    Abstract translation: 为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗目标的分子，构建了代表32,256个基因的cDNA微阵列，分析了19例食管鳞状细胞癌（ESCCS）的表达谱 ）通过激光捕获显微切割纯化。 本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。 这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。 此外，本文公开了与淋巴结转移和手术后复发相关的基因。 在候选分子靶基因中，进一步表征了人类上皮细胞转化序列2致癌基因（ECT2）和细胞分裂周期45，酿酒酵母，同系物样（CDC45L）。 用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。 因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。 此外，本发明人鉴定了DKK1作为肺癌，食管癌等癌症诊断用潜在生物标志物，并预测了这些疾病患者的预后差。 本发明人检查的大多数肺癌和食管癌组织中DKK1被特异性过度表达，并且在大量患有这些肿瘤的患者的血清中升高。 DKK1与其他肿瘤标志物结合可显着提高癌症诊断的敏感性。 此外，该分子也是开发抗体治疗等治疗方法的可能候选者。

    METHOD OF DIAGNOSING BLADDER CANCER
    29.
    发明申请
    METHOD OF DIAGNOSING BLADDER CANCER 审中-公开
    诊断膀胱癌的方法

    公开(公告)号：WO2006085684A9

    公开(公告)日：2006-10-19

    申请号：PCT/JP2006302684

    申请日：2006-02-09

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

    Inventor： NAKAMURA YUSUKE ,  KATAGIRI TOYOMASA ,  NAKATSURU SHUICHI

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2500/00

    Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.

    Abstract translation: 本文描述了用于检测和诊断膀胱癌（BLC）的客观方法。 在一个实施方案中，诊断方法包括确定区分BLC细胞和正常细胞的BLC相关基因的表达水平。 本发明进一步提供了使用在具有淋巴结转移的膀胱癌细胞中具有独特改变的表达模式的BLC相关基因来预测和预防膀胱癌转移的手段。 最后，本发明提供了筛选可用于治疗膀胱癌的治疗剂的方法，治疗膀胱癌的方法以及针对膀胱癌接种受试者的方法。 具体而言，本申请提供了在膀胱癌中表达显着升高的新型人基因C2093，B5860N和C6055。 由基因编码的基因和多肽可以用于例如膀胱癌的诊断，作为开发针对该疾病的药物的靶分子，以及用于减弱膀胱癌的细胞生长。

    COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER
    30.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING PANCREATIC CANCER 审中-公开
    用于治疗胰腺癌的组合物和方法

    公开(公告)号：WO2005090572A3

    公开(公告)日：2006-04-13

    申请号：PCT/JP2005005619

    申请日：2005-03-18

    Applicant: ONCOTHERAPY SCIENCE INC ,  UNIV TOKYO ,  NAKAMURA YUSUKE ,  NAKAGAWA HIDEWAKI

    Inventor： NAKAMURA YUSUKE ,  NAKAGAWA HIDEWAKI

    IPC: A61K31/7088 ,  C12N15/113

    CPC classification number: C12N15/1138 ,  C12N2310/14 ,  C12N2310/53

    Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a siRNA that inhibits expression of PCDH1, CDH3 or GPR107. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example pancreatic cancer cell, particularly pancreatic ductal adenocarcinoma (PDACa).

    Abstract translation: 本发明的特征在于通过使细胞与抑制PCDH1，CDH3或GPR107的表达的siRNA的组成接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还包括可用于所提供的方法的产品，包括核酸序列和载体以及包含它们的组合物。 本发明还提供了抑制肿瘤细胞的方法，例如胰腺癌细胞，特别是胰腺导管腺癌（PDACa）。

Patent Agency Ranking